vascuCAP vs Imbio PHA (4.0.0)
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (vascuCAP) specializes in analyzing CT angiograms to quantify plaque composition and assess cardiovascular risk for conditions like stroke and heart attack. In contrast, Tool B (Imbio PHA) focuses on CT pulmonary angiograms (CTPA) to measure cardiac structures for the diagnosis and risk stratification of pulmonary embolism and hypertension. While both are FDA-cleared AI tools for cardiovascular imaging, their distinct clinical applications and specific analytical outputs make them adjacent rather than direct competitors.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
vascuCAP (now ElucidVivo/PlaqueIQ) is designed for non-invasive CT angiography analysis to quantify plaque composition, assess cardiovascular risk for stroke and heart attack, and optimize treatment decisions. Imbio PHA (4.0.0) processes CT pulmonary angiogram (CTPA) scans to measure cardiac structures, assess potential right ventricular dilation, and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.
vascuCAP quantifies plaque composition, including lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage. Imbio PHA automatically measures right and left ventricle diameters, main pulmonary artery and aorta diameters, and calculates RV/LV and PA/Ao ratios.
vascuCAP analyzes non-invasive CT angiography (CTA) scans. Imbio PHA processes CT pulmonary angiogram (CTPA) scans.
vascuCAP features histologically-validated plaque quantification and characterization, with its algorithms validated by expert pathologists using tissue specimens as a truth standard. Imbio PHA's clinical performance validation has shown accuracy in measuring RV/LV and PA/Ao ratios when compared with expert radiologists.
Imbio PHA offers rapid, fully-automated assessment, typically providing results in minutes. The provided information for vascuCAP indicates that its analysis is performed on-site in minutes.